ValeantªÑ»ù¤@«×¶^¨â¦¨
¬ü²³°|«P¬dÃļt¤j´T´£»ù
¡i©ú³ø±M°T¡j¬ü°ê²³Ä³°|¥Á¥DÄÒijûn¨D¦V¤j´T´£»ùÃļtµo¥X¸ê®Æ¤å¥ó¶Ç¥l¥O¡A¥[®³¤j»sÃĤj¤âValeant Pharmaceuticals International Inc.(¥N¸¹VRX)ªÑ»ù©P¤@´¿¤j¶^¨â¦¨¡C¬ü°ê¬F«È³ÌªñP¤O¹K¤îÃļt±N·s¦¬Áʱo¨ÓÃĪ««æ¼@´£»ùªº·¼é¡C
¦b¤@«Ê¦V²³Ä³°|ºÊ¹î¤Î¬F©²§ï²©eû·|¥D®uJason Chaffetzµo¥Xªº¨ç¥ó¤¤¡A18¦W¥Á¥DÄÒ²³Ä³ûºÙ¡A·í»sÃĤ½¥q¶R¤J´ÚÃÄ«á´£»ù®É¡A¥²¶·Åý³o¨ÇÃļt©Ó¾á³d¥ô¡C¨ç¥ó¯S§O«ü¥XValeantªº¤ßŦ¥ÎÃÄNitropress©MIsuprel¬°¨Ò¡A¦bValeantÁʱo¨âÃĪº¾P°âÅv«á·í¤é¡A»ù®æ¤À§O‘B¤É212%©M525%¡C
¦b¥Á¥DÄÒÁ`²ÎÔ¿ï¤H§Æ©Ô¨½¤W©Pªí¥Ü·|§ï²»sÃÄ·~¡A¥H«OÅ@®ø¶OªÌ§K¨ü¥[»ù¤§¨a¤U¡AValeantªÑ»ù¤w¬O³s¶^²Ä¤T¤Ñ¡C§Æ©Ô¨½ªºµo¨¥¬O¦^À³¶Ç´C³ø¹D®É§@¥Xªº¡A·í®É¶Ç´C«ü«e¹ï¨R°òª÷¸g²z¡B²{Turing Pharmaceuticals AG¦æ¬FÁ`µôMartin Shkreli¦b¦¬Áʱo¤@ºØ¦³¼Æ¤Q¦~¾ú¥vªº§Ü¥Í¯À«á¡A±N¨ä»ù®æ´£°ª50¿¡A¥Ñ¨C²É13.5¬ü¤¸¥[¦Ü750¬ü¤¸¡C
§Æ©Ô²ú´£¥X¤@Óp¹º¯ó¹Ï¡A¥]¬A³W©w¥²¶·¦b¬ã¨s¶}µo¤è±§ë¸ê¡A¦¹¤@«Øij¶Õ±N¹ïValeant¤§Ãþʾa³s¦ê¦¬ÁÊ¥H«Ø¥ßÔ¿ïÃĪ«¸sªº¤½¥q³y¦¨·l®`¡CValeant¥h¦~ªá¤F2.46»õ¬ü¤¸¦b¬ã¨s¤è±¡A»·¤ñ¦PÃþ³W¼ÒªºÃļt¬°¤Ö¡C
Valeantµo¨¥¤HLaurie Little¥¼¦³§Y®É¦^À³¡A¦æ¬FÁ`µôMike Pearson©P¤@¦Vû¤uªí¥Ü¡A¤½¥q¥Í·N¼Ò¦¡¨Ã¤£Ê¿à¤j´T¥[»ù¡A¦Ó¬F«Èn¨D¹K¤î¬F©²ªºÃĪ«Àv¥I©IÁn¤é°ª¡A¤]¤£·|¼vÅT¤½¥q·~ÁZ¡C
¦b¥Á¥DÄÒ¤H±N¨ç¥ó¤½¶}¤§«e¡APearson¦b¤@«ÊP¹µû¨ç¥ó¤¤»¡¡J¡uValeant¦³¯à¤O¹FP±j«l¤º¥Í¼Wªø¡A§Y¨Ï°²³]ÃÄ»ù¥u§@¤p´T¥[»ù¬Æ©Î¤£´£»ù¡A³£µL¼vÅT¡C¡v¬ü°ê¬F©²¶}¤äp¹ºªºÃĪ«Àv¥I¡A¦ûValeantÁ`¦¬¤Jªº15%¡CPearson«ü¥X¡A¦¹¤ñ²v¸û¨ä¥L¤jÃļt¬°§C¡C
ValeantªÑ»ù©P¤@¦b¯Ã¬ù¦¬³ø166.33¬ü¤¸¡A¶^33.14¬ü¤¸¡A©Î16.61%¡C¦b¦hÛ¦h¡A«h¦¬³ø221.81¤¸¡A¶^43.20¤¸¡A©Î16.30%¡C